| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 26, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Open market or private sale of non-derivative or derivative security | 3,577 | $55.19 | 7,400 |
| Jul 26, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Open market or private sale of non-derivative or derivative security | 7,400 | $54.74 | -- |
| Jul 26, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Other acquisition or disposition | -- | -- | 1,388 |
| Jul 25, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | $15.64 | 25,000 |
| Jul 25, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 6,949 | $56.26 | 18,051 |
| Jul 25, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 7,074 | $56.26 | 10,977 |
| Jul 25, 2011 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 25,000 | -- | 49,428 |
| Dec 14, 2010 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 3,264 | -- | 3,264 |
| Dec 14, 2010 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 28,736 | -- | 28,736 |
| Dec 18, 2009 |
SVP Clinical Development
|
SVP Clinical Development | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 5,457 | -- | 5,457 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.